(S)-[6]-Gingerol enhances glucose uptake in L6 myotubes by activation of AMPK in response to [Ca²⁺]

Yiming Li, Van H Tran, Nooshin Koolaji, Colin C Duke, Basil D Roufogalis

Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia

Received, June 18, 2013; Accepted, June 30, 2013; Published, July 4, 2013

ABSTRACT – PURPOSE. The aim of this study was to investigate the mechanism of (S)-[6]-gingerol in promoting glucose uptake in L6 skeletal muscle cells. METHODS. The effect of (S)-[6]-gingerol on glucose uptake in L6 myotubes was examined using 2-[1,2-3H]-deoxy-D-glucose. Intracellular Ca²⁺ concentration was measured using Fluo-4. Phosphorylation of AMPKα was determined by Western blotting analysis. RESULTS. (S)-[6]-Gingerol time-dependently enhanced glucose uptake in L6 myotubes. (S)-[6]-Gingerol elevated intracellular Ca²⁺ concentration and subsequently induced a dose- and time-dependent enhancement of threonine172 phosphorylated AMPKα in L6 myotubes via modulation by Ca²⁺/calmodulin-dependent protein kinase kinase. CONCLUSION. The results indicated that (S)-[6]-gingerol increased glucose uptake in L6 skeletal muscle cells by activating AMPK. (S)-[6]-gingerol, a major component of Zingiber officinale, may have potential for development as an antidiabetic agent.

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

INTRODUCTION

High calorie intake and low physical activity has led to a dramatic increase in the incidence of type 2 diabetes and in particular hyperglycemia and its complications over the past few decades. A number of intracellular signalling pathways are associated with regulation of blood glucose and may be targets of drug action. AMP-activated protein kinase (AMPK) has a key role in regulating energy fuel, as demonstrated at both the cellular and whole body level (1, 2). AMPK is a heterotrimeric complex comprised of one catalytic subunit (α) and two regulatory subunits (β and γ). Activation of AMPK occurs by phosphorylation at threonine172 (Thr172) on the loop of the catalytic domain of the α-subunit (3, 4). Currently, two major upstream kinases have been identified, the LKB1/STRAD/MO25 complex, which maintains the basal level of phosphorylation of AMPKαThr172, and the Ca²⁺/calmodulin-dependent protein kinase (CAMKK), which is triggered by increased intracellular Ca²⁺ concentration (5-7).

In skeletal muscle AMPK activation in response to metabolic stress leads to a switch of cellular metabolism from anabolic to catabolic states. Studies with AMP-mimetic compound 5 – aminomidazole – 4 – carboxamide – 1 – β – D - ribofuranoside (AICAR) showed that acute activation of AMPK increased glucose uptake by promoting glucose transporter (GLUT4) translocation to the plasma membrane as well as facilitated fatty acid influx and β-oxidation (8-10). Repetitive AMPK activation results in up-regulation of numerous genes and proteins involved in energy metabolism.

(S)-[6]-Gingerol ( ( S ) – 5 – hydroxyl – 1 - [ 4’ – hydroxyl – 3’ – methoxyphenyl ] – 3 - decanone) is the major pungent phenolic component in ginger (Zingiber officinale Roscoe, Family Zingiberaceae). Recent studies have shown that (S)-[6]-gingerol reduced blood glucose levels in diabetic animal models and promoted glucose uptake in in vitro cell-based experiments (11-14). However there are limited studies elucidating the molecular mechanisms associated with the action of (S)-[6]-gingerol. The present study aimed to investigate the effect of (S)-[6]-gingerol on glucose uptake in L6 skeletal muscle cells, and to investigate its potential to mediate AMPK activation and the role of the intracellular Ca²⁺ signal in this action.

Corresponding Author: Dr Colin Duke; Faculty of Pharmacy, The University of Sydney; NSW, Australia; Email: colin.duke@sydney.edu.au
MATERIALS AND METHODS

Materials
L6 rat myoblast culture was purchased from European Collection of Cell Cultures (ECACC Salisbury, UK). Fluo-4 NW Calcium Assay Kit and Lipofectamine 2000 were purchased from Invitrogen (Mulgrave, Vic Australia). The AMPK and ACC Antibody Sampler Kit (# 9957) and LumiGLO® and Phototope®-HRP detection reagent were obtained from Cell signaling (Arundel, Queensland Australia). 2-Deoxy-D-glucose (Grade III) and predesigned sets of duplexed siRNA were purchased from Sigma-Aldrich (Castle Hill, NSW Australia). 2-[1,2-3H]-Deoxy-D-glucose was purchased from PerkinElmer (Massachusetts, USA).

Preparation of (S)-[6]-gingerol
(S)-[6]-Gingerol ((S)-5-Hydroxy-1-[4'-hydroxy-3'-methoxyphenyl]-3-decanone) was isolated from total ginger extract as described previously (14). Briefly, freeze dried powder of ginger rhizome (1 Kg) (Grade A, batch No. 9240089, provided by Buderim Ginger Limited, Queensland, Australia) was extracted with ethyl acetate (3 L) with stirring at room temperature. The filtrate was collected and evaporated under reduced pressure to afford a liquid residue (55 g) as total ginger extract. (S)-[6]-Gingerol (purity of 94.0%) was obtained by further purification using a normal phase short column vacuum chromatography (NP-SCVC) system (14).

Cell culture
L6 myoblasts were maintained in α-minimal essential medium with 10% fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO₂. When myoblasts grew to confluence, cells were allowed to fuse into multinucleated myotubes in α-MEM containing 2% heat-treated newborn calf serum (CS).

Glucose uptake assay
L6 myoblasts were seeded in 48-well plates at a density of 4×10⁴ cells/cm² and allowed to fuse into myotubes as described above. The assays were performed when over 70% myotubes had formed. On the day of testing, the cells were washed twice with phosphate-buffered saline solution (PBS), and starved in serum-free α-MEM in 0.5% (w/v) bovine serum albumin containing treatment samples for 5 hours, followed by a quick wash with Krebs-Ringer-phosphate-Hepes buffer (KRPH, 20 mM Hepes, 5 mM KH₂PO₄, 1 mM MgSO₄, 136 mM NaCl, 4.7 mM KCl, 1 mM CaCl₂, pH 7.4).

Test samples were incubated for the indicated time periods. Where inhibitors were used, cells were pre-treated for 30 minutes before adding treatment compounds. The cells were then incubated in KRPH and 2-deoxy-glucose uptake was measured over a 5 minute period (100 μM 2-deoxy-D-glucose with 2-[1,2-3H]-deoxy-D-glucose 0.3 μCi/well) at room temperature (20-25°C). The uptake was terminated by 5 quick washes with ice-cold PBS. The plates were air-dried for 15 minutes and cells were lysed in 0.05 N NaOH solution. The radioactivity of 2-[1,2-3H]-deoxy-D-glucose in the cell lysate was determined in a scintillation counter.

Intracellular Ca²⁺ concentration
L6 myoblasts were seeded in 96-well black clear bottom plates and differentiated into myotubes as described above. The intracellular Ca²⁺ concentration was measured using Fluo-4 NW Calcium Assay Kit following the manufacturer’s instruction. Briefly, on the day of experiment, the cells were washed twice with PBS, then 100 μl of Fluo-4 NW solution was added quickly to each well and incubated at 37°C for 30 minutes and left at room temperature for a further 30 minutes. Addition of treatment compounds was followed by immediate measurement of the fluorescence intensity of Fluo-4 at ex 485 nm / em 520 nm by a real-time Novostar plate reader over 120 second time periods.

Western blot analysis
L6 myotubes were treated with (S)-[6]-gingerol for the indicated time periods. Where inhibitors were used, cells were pre-treated for 30 minutes before adding treatment compounds. Then the cells were washed twice with PBS, and lysed with RIPA buffer containing protease inhibitor and phosphatase inhibitor cocktail. The protein content of cell lysates was determined by Micro BCA™ protein assay kit. Thirty micrograms of protein was resolved on 4-12% SDS-PAGE, and then transferred to nitrocellulose membrane. The membrane was blocked with 5% BSA/TBST for 1 hour, incubated with primary antibody overnight at 4°C, then probed with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5000, Cell Signaling) for 1 hour. Primary antibodies used were monoclonal rabbit anti-phospho-AMPKα (Thr172) (1:2500, Cell Signaling), monoclonal rabbit anti-AMPKα (1:2500, Cell Signaling), polyclonal rabbit anti-phospho-acetyl-CoA carboxylase (Ser79) (1:2500, Cell Signaling), and monoclonal rabbit anti-acetyl-CoA carboxylase (1:2500, Cell Signaling). Protein
bands were detected with LumiGLO® and Phototope®-HRP detection reagent. The intensity of bands was determined using the ImageJ image processing program.

**AMPKα1/α2 siRNA knockdown**

AMPKα1/α2 siRNA were transfected for 48 hours when 60-70% of L6 myoblasts were differentiated into myotubes. The siRNA sequence of SASI_Rn01_00074869 — AMPKα1 is 5’CCUAUGAAGAGGCCACAA3’, SASI_00067553 — AMPKα2 is 5’CCUAUGAUUGCUAACGUCAU3’, and the positive control GAPDH is 5’CCUUCUCUCGAAUACCAU3’. The unrelated siRNA control was MISSION® Universal Negative Control (SIC001, Sigma-Aldrich). The transfection and knockdown efficiency of siRNA were determined 48 hours post transfection (data available on request). AMPKα1/α2 protein expression and glucose uptake assays were performed after 48 hours of transfection.

**STATISTICS**

All data are presented as mean ± SEM of three independent experiments. Results were analysed using one way analysis of variance (ANOVA) followed by the Newman-Keuls post hoc test. Differences were considered significant when P values were less than 0.05 (P < 0.05).

**RESULTS**

**(S)-[6]-Gingerol enhances glucose uptake in L6 myotubes**

The time dependent effect of (S)-[6]-gingerol on glucose uptake in L6 myotubes was examined. Glucose uptake was observed to increase from 1 to 24 hours in L6 myotubes treated with (S)-[6]-gingerol (150 µM). A significant increase was achieved within 1 hour of treatment (Figure 1).

**(S)-[6]-Gingerol enhances phosphorylated-AMPK α-subunit in L6 myotubes**

Our previous study demonstrated that (S)-[6]-gingerol enhanced glucose uptake in L6 myotubes (14). The involvement of AMPK and phosphorylated AMPKαThr172 (p-AMPKαThr172) in (S)-[6]-gingerol stimulated glucose uptake were examined after (S)-[6]-gingerol (150 µM) treatment by Western blot analysis. P-AMPKαThr172 was found to be elevated rapidly and reached a peak of 5.5-fold over basal level at 10 minutes, then declined gradually and was maintained at 3.5-fold thereafter (Figure 2A). Consistent with the increase of p-AMPKαThr172, phosphorylated acetyl-CoA carboxylase (p-ACCSer79), one of the downstream targets of AMPK, was elevated maximally within 5 min and was maintained thereafter (Figure 2B).

**(S)-[6]-Gingerol -induced AMPK phosphorylation was mediated by CaM KK in L6 myotubes**

The Ca²⁺ signal is involved in a broad range of skeletal muscle activities. (S)-[6]-Gingerol increased intracellular Ca²⁺ concentration in a dose-dependent manner within 1 minute in L6 myotubes (Figure 3). The increase appeared more gradual than the rapid increase seen with carbachol as a control, which indicated that (S)-[6]-gingerol-induced intracellular Ca²⁺ rise occurred through a mechanism distinct from that with carbachol.

P-AMPKαThr172 increased significantly in L6 myotubes treated with the calcium ionophore A23187 (1 µM). AMPK activator AICAR (1 mM) also increased the AMPKαThr172 phosphorylation level, and the activation by AICAR was blocked by the AMPK inhibitor Compound C, which was consistent with a previous study (15). (S)-[6]-Gingerol (50, 100 and 150 µM) dose-dependently increased AMPKαThr172 phosphorylation levels. Addition of the CaMKK inhibitor STO609 (16) (2.67 µM) 30 minutes before (S)-[6]-gingerol (150 µM) treatment, decreased p-AMPKαThr172 level drastically compared to that with (S)-[6]-gingerol alone (Figure 4). These results indicated that (S)-[6]-gingerol- induced AMPKα phosphorylation was modulated by raised intracellular Ca²⁺ and mediated via CaM KK.

We next investigated the role of Ca²⁺ and CaM KK activation in (S)-[6]-gingerol-stimulated glucose uptake. Pretreatment of L6 myotubes with the intracellular Ca²⁺ chelator BAPTA-AM abolished the stimulation of glucose uptake by (S)-[6]-gingerol. Glucose uptake was also abolished by pretreatment with the CaM KK inhibitor STO609 (Figure 5). The significant increment of glucose uptake by AICAR was diminished by adding its inhibitor Compound C. The calcium ionophore A23187 increased glucose uptake slightly (1.27-fold), and it was decreased by adding calcium chelator BAPTA-AM.
Figure 1. Effect of (S)-[6]-gingerol on glucose uptake in L6 myotubes. L6 myotubes were treated with (S)-[6]-gingerol (150 µM) for 1, 3, 5, 20 and 24 hours, as described in Materials and Methods. 2-Deoxy-D-glucose (2-DG) uptake was measured over 5 minutes at room temperature. All data are presented as mean ± SEM of 3 independent experiments performed in triplicate. * P < 0.05, *** P < 0.001 vs. Control.

Figure 2. Time-dependent effect of (S)-[6]-gingerol on AMPKαThr172 and ACCSer79 phosphorylation in L6 myotubes. The levels of phosphorylated AMPKαThr172 (A) and ACCSer79 (B) were analysed by Western blot at 1, 3, 5, 20, 40 and 60 minutes with (S)-[6]-gingerol (150 µM) treatment. Data are from 3 independent experiments.

Which AMPKα isoform is involved in glucose uptake?
To determine which AMPKα isoform was dominant in mediating (S)-[6]-gingerol stimulated glucose uptake in L6 myotube, AMPKα1 or AMPKα2 was selectively knocked down by transfecting their corresponding siRNAs. The transfection efficiency was tested using a FAM-conjugated MISSION® Universal Negative Control, and achieved 80.43% knockdown of target gene using GAPDH positive control (data not shown but available as Supplementary information).

A significant reduction in protein expression was found to occur to a similar extent in both AMPKα1 and AMPKα2 knockdown L6 myotubes (Figure 6A and 6B).
Figure 3. Effect of (S)-[6]-gingerol on [Ca\textsuperscript{2+}] in L6 myotubes. L6 myotubes were incubated with (S)-[6]-gingerol (50, 100 and 150 µM). [Ca\textsuperscript{2+}] was measured using Fluo-4 NW as described in Materials and Methods. Data are presented as % of maximum A23187 (1 µM) response. Data are from 3 independent experiments.

Figure 4. Effect of (S)-[6]-gingerol on AMPK\textsuperscript{α} Thr172 phosphorylation. AMPK\textsuperscript{α} Thr172 phosphorylation (p-AMPK\textsuperscript{α} Thr172) in L6 myotubes was detected following treatment with (S)-[6]-gingerol, A23187 (1 µM) and AICAR (1 mM) for 10 minutes. Inhibitors Compound C and STO609 were added 30 minutes prior to the treatments. The graph is the representative image of three independent experiments.

The (S)-[6]-gingerol stimulated glucose uptake was diminished in AMPK\textalpha and AMPK\textalpha/\textalpha knockdown L6 myotubes, whilst the increment of glucose uptake by (S)-[6]-gingerol was not affected in AMPK\textalpha knockdown cells (Figure 6C). This indicated that AMPK\textalpha was the dominant isoform involved in (S)-[6]-gingerol stimulated glucose uptake in L6 skeletal muscle cells.

**DISCUSSION**

The main finding of this study is that (S)-[6]-gingerol increased glucose uptake in L6 skeletal muscle cells, and that the stimulation involves AMPK\textalpha activation. Though mounting evidence has suggested that ginger and its major chemical components were effective in alleviating hyperglycaemia and dyslipidaemia, the mechanisms underlying these actions remained largely unclear (16). To our knowledge this is the first study to reveal the role of AMPK in (S)-[6]-gingerol stimulated glucose uptake. It has been well established that AMPK plays an important role in mediating energy homeostasis. Recent evidence showed that AMPK activation facilitated acute glucose uptake by triggering glucose transporter GLUT4 trafficking via phosphorylation of TBC1D1, a downstream protein shared in the insulin signalling transduction pathway (17, 18). AMPK activation also up-regulated the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1\textalpha), a transcriptional cofactor regulating mitochondrial biogenesis and GLUT4 expression (19-22). Therefore AMPK has been considered a potential
target for developing therapeutic agents to treat type 2 diabetes (23).

In support of a role of AMPK in \((S)\)\-[6]-gingerol stimulated glucose uptake we showed that the downstream target of AMPK, acetyl-CoA carboxylase (ACC), was also phosphorylated in \((S)\)\-[6]-gingerol treated L6 myotubes. ACC plays a key role in de novo fatty acid biosynthesis by catalysing carboxylation of acetyl-CoA to form malonyl-CoA. Accumulation of malonyl-CoA inhibits carnitine palmitoyltransferase I (CPT1) to transfer long-chain fatty acyl-CoA from cytosol into mitochondria for further oxidation (24). A decrease of malonyl-CoA was reported to diminish insulin resistance in fat-fed rats (25). Phosphorylation of Ser79 in ACC will subsequently inactivate the enzyme, leading to a switch of the cellular metabolism from energy storage to expenditure.

Calcium is a universal secondary messenger involved in a broad range of cell activities (26, 27). \((S)\)\-[6]-gingerol has been shown to evoke intracellular Ca\(^{2+}\) transients in dorsal root ganglion (DRG) neurones by activating vanilloid (TRPV1) receptor (28). \((S)\)\-[6]-Gingerol was also able to induce a significant rise of [Ca\(^{2+}\)]\(_i\) via stimulating extracellular Ca\(^{2+}\) influx and intracellular Ca\(^{2+}\) release in kidney cells (29). Our data showed that \((S)\)\-[6]-gingerol induced a gradual increase of intracellular Ca\(^{2+}\) concentration, but the molecular target of this action is as yet unidentified. The time course of [Ca\(^{2+}\)]\(_i\) increase by \((S)\)\-[6]-gingerol was consistent with the time course for induction of p-AMPK\(^{\alpha\ Thr172}\), which occurred rapidly and reached a peak at 10 minutes. To examine whether AMPK\(^{\alpha\ Thr172}\) phosphorylation by \((S)\)\-[6]-gingerol was mediated by the CaMKK, a selective CaMKK inhibitor, STO609, was added to L6 skeletal muscle cells before treatment with \((S)\)\-[6]-gingerol. It was found that STO609 inhibited AMPK\(^{\alpha\ Thr172}\) phosphorylation levels significantly compared to \((S)\)\-[6]-gingerol alone (Figure 4). In parallel, \((S)\)\-[6]-gingerol-stimulated glucose uptake was completely abolished by STO609 (Figure 5). These results suggested that the enhancement of glucose uptake by \((S)\)\-[6]-gingerol was mediated through the Ca\(^{2+}\)/CaMKK-AMPK pathway.

The glucose transporter GLUT4 is the principle isoform responsible for glucose clearance in peripheral tissues. Though the dynamic nature of GLUT4 has been extensively studied in the past few decades, the role of Ca\(^{2+}\) in mediating GLUT4 trafficking is not completely understood (30).

Figure 5. Mechanism of \((S)\)\-[6]-gingerol activation of glucose uptake in L6 myotubes. L6 myotubes were treated with \((S)\)\-[6]-gingerol (150 \(\mu\)M), AICAR (1 mM) or A23187 (100 nM) for 1 hour, as described in Materials and Methods. Where BAPTA-AM (10 \(\mu\)M), Compound C (10 \(\mu\)M) or STO609 (2.67 \(\mu\)M) were used, they were preincubated with L6 myotubes for 30 minute before treatments. 2-Deoxy-D-glucose (2-DG) uptake was measured over 5 minutes at room temperature. Data are the mean ± SEM of 3 independent experiments performed in triplicate. * \(P < 0.05\) vs. Control.
Recent studies supported the Ca$^{2+}$ requirement for GLUT4 trafficking along the cortical actin filaments and fusion into the plasma membrane (31-33). Our previous study showed that (S)-[8]-gingerol, a more potent homologue of (S)-[6]-gingerol, enhanced glucose uptake either in the presence or absence of insulin by promoting GLUT4 translocation and fusion into plasma membrane (14). In this study the intracellular Ca$^{2+}$ chelator BAPTA-AM completely abolished the effect of (S)-[6]-gingerol on glucose uptake in L6 myotubes, suggesting a pivotal role of Ca$^{2+}$ in GLUT4 dynamics. The same result was observed in 3T3-L1 adipocytes in a previous study (34).

AMPK is highly expressed in skeletal muscle tissue (35). The two isoforms of the catalytic subunit AMPK$\alpha$1 and AMPK$\alpha$2 are encoded by distinct genes (36). It has been suggested that AMPK$\alpha$1 and AMPK$\alpha$2 have different physiological roles in mediating energy homeostasis. AMPK$\alpha$2 tends to be more sensitive to cellular AMP variation (37). The results from
isoform knockout rodent models demonstrated that AMPKα2 knockout mice were resistant to AICAR stimulated glucose uptake and presented insulin resistance (38, 39). However, it was found that in obese subjects, the basal AMPKα1 activity was reduced significantly compared to lean control, whilst AMPKα2 activity remained at the same level (40). In AMPKα1 knockout mice, low intensity contraction-stimulated glucose uptake in skeletal muscle was markedly decreased, but this was not the case in AMPKα2 knockout mice. A recent study showed that caffeine increased AMPKα1 activity and glucose uptake in rat epitrochlearis muscle without affecting energy status (41). In the present study, it was found that (S)-[6]-gingerol stimulated increase of glucose uptake was completely abolished in AMPKα1 knockdown L6 myotubes, which indicated that (S)-[6]-gingerol increased glucose uptake preferentially via activation of the AMPKα1, rather than the AMPKα2 isoform.

CONCLUSION

The present study showed a significant and rapid increase of glucose uptake in (S)-[6]-gingerol treated L6 myotubes. This action of (S)-[6]-gingerol was associated with an elevation of cytosolic Ca^2+ concentration and enhancement of levels of phosphorylated AMPKαThr172, preferentially through the AMPKα1 isoform. Our data supports (S)-[6]-gingerol, the major pungent component of ginger (Zingiber officinale), as a candidate potential hypoglycaemic agent at least in part through its effectiveness in promoting glucose uptake in skeletal muscle.

ACKNOWLEDGMENT

This work was supported by an Australian Research Council Linkage grant (LP0989786).

REFERENCES

1. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic regulator of whole-body energy homeostasis. Trends in Molecular Medicine. 2008; 12: 539-549.
2. Witzak CA, Sharoff CG, Goodyear LJ. AMP-activated protein kinase in skeletal muscle: From structure and localization to its role as a master regulator of cellular metabolism. Cellular and Molecular Life Sciences. 2008; 23: 3737-3755.
3. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. Characterization of the AMP-activated protein kinase isozyme from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. The Journal of biological chemistry. 1996; 44: 27879-27887.
4. Stein SC, Woods A, Jones NA, Davison MD, Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem J. 2000; 437-443.
5. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995; 45: 27186-27191.
6. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003; 22: 2004-2008.
7. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem. 2006; 35: 25336-25343.
8. Merrill GF, Kurth EJ, Rasmussen BB, Winder WW. Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle. J Appl Physiol. 1998; 5: 1909-1914.
9. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol. 1999; 8: 1667-1671.
10. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5'-AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 1999; 8: 1667-1671.
11. Nammi S, Sreemantula S, Roufogalis BD. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic & clinical pharmacology & toxicology. 2009; 5: 366-373.
12. Sekiya K, Ohtani A, Kusano S. Enhancement of insulin sensitivity in adipocytes by ginger. Biofactors. 2004; 1-4: 153-156.
13. Noipha K, Ratanchayavong S, Ninla-Aesong P. Enhancement of glucose transport by selected plant foods in muscle cell line L6. Diabetes Res Clin Pract. 2010; 2: e22-26.
14. Li Y, Tran VH, Duke CC, Roufogalis BD. Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. Planta Med. 2012; 14: 1549-1555.
15. Hutchinson DC, Bentgsson T. AMP-activated protein kinase activation by adrenergic receptors in L6 skeletal muscle cells: mediation by alpha1-adrenoceptors causing glucose uptake. Diabetes. 2006; 55: 682-690.
16. Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R. STO-609, a specific inhibitor
of the Ca(2+/-)calmodulin-dependent protein kinase kinase. J Biol Chem. 2002; 18: 15813-15818
17. Pehmoller C, Treebak JT, Birk JB, Chen S, Mackintosh C, Hardie DG, Richter EA, Wojtaszewski JF. Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle. Am J Physiol Endocrinol Metab. 2009; 3: E665-675.
18. Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, Mackintosh C. Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008; 2: 449-459.
19. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell metabolism. 2005; 1: 15-25.
20. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 4: 145-151.
21. Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans. 2011; 1: 1-13.
22. Wu Z, Puigserver P, Andersson U, Zhang C, Adelman G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999; 1: 115-124.
23. Gruzman A, Babai G, Sasson S. Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations. Rev Diabet Stud. 2009; 1: 13-36.
24. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004; 4: 340-351.
25. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D, Newgard CB. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004; 3: 268-274.
26. Clapham DE. Calcium signaling. Cell. 2007; 6: 1047-1058.
27. Beredridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003; 7: 517-529.
28. Dedov VN, Tran VH, Duke CC, Connor M, Christie MJ, Mandadi S, Roufogalis BD. Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br J Pharmacol. 2002; 6: 793-798.
29. Chen CY, Chen CH, Kung CH, Kuo SH, Kuo SY. [6]-gingerol induces Ca2+ mobilization in Madin-Darby canine kidney cells. J Nat Prod. 2008; 1: 137-140.
30. Foley K, Boguslavsky S, Klip A. Endocytosis, recycling, and regulated exocytosis of glucose transporter 4. Biochemistry. 2011; 15: 3048-3061.
31. Lopez JA, Burchfield JG, Blair DH, Mele K, Ng Y, Valtzton P, James DE, Hughes WE. Identification of a distal GLUT4 trafficking event controlled by actin polymerization. Mol Biol Cell. 2009; 17: 3918-3929.
32. Furuta A, Tanaka M, Omata W, Nagasawa M, Kojima I, Shibata H. Microtubule disruption with BAPA and dimethyl BAPA by a calcium chelation-independent mechanism in 3T3-L1 adipocytes. Endocr J. 2009; 2: 235-243.
33. Worrall DS, Olefsky JM. The effects of intracellular calcium depletion on insulin signaling in 3T3-L1 adipocytes. Mol Endocrinol. 2002; 2: 378-389.
34. Whitehead JP, Molero JC, Clark S, Martin S, Meneilly G, James DE. The role of Ca2+ in insulin-stimulated glucose transport in 3T3-L1 cells. J Biol Chem. 2001; 27816-27824.
35. Verhoeven AJ, Woods A, Brennan CH, Hawley SA, Hardie DG, Scott J, Beri RK, Carling D. The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Alternative splicing and tissue distribution of the mRNA. Eur J Biochem. 1995; 2: 236-243.
36. Woods A, Salt I, Scott J, Hardie DG, Carling D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 1996; 2-3: 347-351.
37. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J. 1998; 177-187.
38. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolaas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest. 2003; 1: 91-98.
39. Jorgensen SB, Viollet B, Andreelli F, Froisig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem. 2004; 2: 1070-1079.
40. Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes. 2005; 11: 3154-3160.
41. Egawa T, Hamada T, Ma X, Karaitke K, Kameda N, Masuda S, Iwanaka N, Hayashi T. Caffeine activates preferentially alpha1-isoform of 5'-AMP-activated protein kinase in rat skeletal muscle. Acta Physiol (Oxf). 2011; 2: 227-238.